Lucia Bio is developing highly selective spleen tyrosine kinase (Syk) inhibitors for potential application in peripheral immunology, neurology and haematology oncology.
A collaboration between the University of Queensland Emory Drug Discovery Initiative (QEDDI) and Molecule to Medicine (MTM), Lucia Bio is capitalising on QEDDI’s focused discovery and development of oral small molecule inhibitors of Syk, built on the deep knowledge of Syk and dependent pathways.
Company Details
Lucia Bio Questions
Lucia Bio's LinkedIn profile is https://au.linkedin.com/company/lucia-bio
Lucia Bio has
4 employees.
View email and phone details for 4
employees at Lucia Bio.
Lucia Bio's industry is
Biotechnology Research
Lucia Bio's top competitors are
Greywolf Therapeutics,
Affivant,
Adiposs,
Uniquest Extension Fund,
Thirtyfivebio,
Melio Bio,
Pathios Therapeutics,
Uniquest,
Molecule To Medicine,
Curlew Bio.
Lucia Bio's categories are Biotechnology Research
Lucia Bio's founding year is 2024
